These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25680530)

  • 21. Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs).
    Richter W; Conti M
    J Biol Chem; 2002 Oct; 277(43):40212-21. PubMed ID: 12177055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.
    Houslay MD; Adams DR
    Biochem J; 2003 Feb; 370(Pt 1):1-18. PubMed ID: 12444918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
    Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
    Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform.
    Shepherd M; McSorley T; Olsen AE; Johnston LA; Thomson NC; Baillie GS; Houslay MD; Bolger GB
    Biochem J; 2003 Mar; 370(Pt 2):429-38. PubMed ID: 12441002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation.
    MacKenzie KF; Wallace DA; Hill EV; Anthony DF; Henderson DJ; Houslay DM; Arthur JS; Baillie GS; Houslay MD
    Biochem J; 2011 May; 435(3):755-69. PubMed ID: 21323643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene.
    Johnston LA; Erdogan S; Cheung YF; Sullivan M; Barber R; Lynch MJ; Baillie GS; Van Heeke G; Adams DR; Huston E; Houslay MD
    Biochem J; 2004 Jun; 380(Pt 2):371-84. PubMed ID: 15025561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle.
    Murthy KS; Zhou H; Makhlouf GM
    Am J Physiol Cell Physiol; 2002 Mar; 282(3):C508-17. PubMed ID: 11832336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis.
    Omar B; Zmuda-Trzebiatowska E; Manganiello V; Göransson O; Degerman E
    Cell Signal; 2009 May; 21(5):760-6. PubMed ID: 19167487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions.
    MacKenzie SJ; Baillie GS; McPhee I; Bolger GB; Houslay MD
    J Biol Chem; 2000 Jun; 275(22):16609-17. PubMed ID: 10828059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function.
    Murdoch H; Vadrevu S; Prinz A; Dunlop AJ; Klussmann E; Bolger GB; Norman JC; Houslay MD
    J Cell Sci; 2011 Jul; 124(Pt 13):2253-66. PubMed ID: 21652625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5.
    Bolger GB; Baillie GS; Li X; Lynch MJ; Herzyk P; Mohamed A; Mitchell LH; McCahill A; Hundsrucker C; Klussmann E; Adams DR; Houslay MD
    Biochem J; 2006 Aug; 398(1):23-36. PubMed ID: 16689683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK).
    Baillie G; MacKenzie SJ; Houslay MD
    Mol Pharmacol; 2001 Nov; 60(5):1100-11. PubMed ID: 11641439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases.
    Richter W; Conti M
    J Biol Chem; 2004 Jul; 279(29):30338-48. PubMed ID: 15131123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting.
    Beard MB; Huston E; Campbell L; Gall I; McPhee I; Yarwood S; Scotland G; Houslay MD
    Cell Signal; 2002 May; 14(5):453-65. PubMed ID: 11882390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A RSK(y) relationship with promiscuous PKA.
    Houslay MD
    Sci STKE; 2006 Aug; 2006(349):pe32. PubMed ID: 16926362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells.
    Millen J; MacLean MR; Houslay MD
    Eur J Cell Biol; 2006 Jul; 85(7):679-91. PubMed ID: 16458997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site.
    Grange M; Sette C; Cuomo M; Conti M; Lagarde M; Prigent AF; Némoz G
    J Biol Chem; 2000 Oct; 275(43):33379-87. PubMed ID: 10938092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphodiesterase 4 and phosphatase 2A differentially regulate cAMP/protein kinase a signaling for cardiac myocyte contraction under stimulation of beta1 adrenergic receptor.
    De Arcangelis V; Soto D; Xiang Y
    Mol Pharmacol; 2008 Nov; 74(5):1453-62. PubMed ID: 18703669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the β-agonist induced hypertrophic response in cardiac myocytes.
    Sin YY; Edwards HV; Li X; Day JP; Christian F; Dunlop AJ; Adams DR; Zaccolo M; Houslay MD; Baillie GS
    J Mol Cell Cardiol; 2011 May; 50(5):872-83. PubMed ID: 21334344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B.
    Johanns M; Lai YC; Hsu MF; Jacobs R; Vertommen D; Van Sande J; Dumont JE; Woods A; Carling D; Hue L; Viollet B; Foretz M; Rider MH
    Nat Commun; 2016 Mar; 7():10856. PubMed ID: 26952277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.